Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale

Sarah A. Holstein; Vera J. Suman; Philip L. McCarthy

doi:10.1038/s41375-018-0359-7

Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale

Sarah A. Holstein, Vera J. Suman, Philip L. McCarthy

Quantitative Health Sciences

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	565-566
Number of pages	2
Journal	Leukemia
Volume	33
Issue number	2
DOIs	https://doi.org/10.1038/s41375-018-0359-7
State	Published - Feb 1 2019

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-018-0359-7

Cite this

@article{6bdbf4215afd40a189ce26659a5abe0a,

title = "Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale",

author = "Holstein, {Sarah A.} and Suman, {Vera J.} and McCarthy, {Philip L.}",

note = "Funding Information: Conflict of interest SAH reports serving as an advisory board member for Celgene, Takeda and Adaptive Biotechnologies, and as a consultant for Celgene and GlaxoSmithKline, outside the submitted work. PLM reports receiving honoraria from Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda and Binding Site, research funding from Celgene, and has served on advisory committees/review panels/board membership for Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda, Binding Site and Karyopharm outside the submitted work. VJS declares that she has no conflict of interest.",

year = "2019",

month = feb,

day = "1",

doi = "10.1038/s41375-018-0359-7",

language = "English (US)",

volume = "33",

pages = "565--566",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale

AU - Holstein, Sarah A.

AU - Suman, Vera J.

AU - McCarthy, Philip L.

N1 - Funding Information: Conflict of interest SAH reports serving as an advisory board member for Celgene, Takeda and Adaptive Biotechnologies, and as a consultant for Celgene and GlaxoSmithKline, outside the submitted work. PLM reports receiving honoraria from Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda and Binding Site, research funding from Celgene, and has served on advisory committees/review panels/board membership for Bristol-Myers Squibb, Celgene, Sanofi-Aventis, Takeda, Binding Site and Karyopharm outside the submitted work. VJS declares that she has no conflict of interest.

PY - 2019/2/1

Y1 - 2019/2/1

UR - http://www.scopus.com/inward/record.url?scp=85059890615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059890615&partnerID=8YFLogxK

U2 - 10.1038/s41375-018-0359-7

DO - 10.1038/s41375-018-0359-7

M3 - Comment/debate

C2 - 30635635

AN - SCOPUS:85059890615

SN - 0887-6924

VL - 33

SP - 565

EP - 566

JO - Leukemia

JF - Leukemia

IS - 2

ER -

Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this